Cassava Sciences rises after US DOJ closes probe into company

Filana Therapeutics

19/02/2026 13:54

** Shares of drug developer Cassava Sciences SAVA.O rise 2.82% to $2.19 premarket

** Co says the U.S. Department of Justice has ended its probe into the company regarding allegations of research misconduct for its experimental Alzheimer's drug simufilam

** Co says probe ended four months after the Justice Department dismissed a criminal indictment accusing former adviser Hoau-Yan Wang, who allegedly submitted false data regarding the drug

** SAVA shares fell 16.1% in 2025

 (Reporting by Gnaneshwar Rajan in Bengaluru)

 ((Gnaneshwar.Rajan@thomsonreuters.com;))